Drugs / UPREVSTOBART
last change Sep 2024 re-read 2 minutes ago

UPREVSTOBART

also known as INCA00186

Monoclonal antibody

Developed for
digestive system cancer · head and neck squamous cell carcinoma
Investigated by
Incyte Corporation

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04989387 Oct 2021 → Sep 2024 digestive system cancer, head and neck squamous cell carcinoma Incyte Corporation Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as UPREVSTOBART ChEMBL registry synonym — accepted as the source's own label CHEMBL5314890
Known as INCA00186 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04989387
Modality Monoclonal antibody CHEMBL5314890